NBIX - Neurocrine Biosciences, Inc.
| Previous Close | 101.790 |
| Open | 100.910 |
| Bid | 100.490 x 1000 |
| Ask | 100.680 x 800 |
| Day's Range | 98.730 - 101.825 |
| 52 Week Range | 44.750 - 106.260 |
| Volume | 412,764 |
| Avg. Volume | 735,911 |
| Market Cap | 8.983B |
| Beta | 2.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.198 |
| Earnings Date | Aug 1, 2018 - Aug 6, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 1995-12-29 |
| 1y Target Est | 110.10 |
- TheStreet.com•5 days ago
5 Stocks That Are Screaming Buys Right Now
Here we used TipRanks' stock screener to pinpoint the most compelling stocks right now. The Street is buzzing about Neurocrine's Ingrezza drug, the first FDA-approved treatment for adults with tardive dyskinesia. On its first quarter earnings call, Neurocrine updated the Street with respect to ongoing market penetration for Ingrezza.
Market Realist•13 days agoVersartis Stock and Its Consistent Rise in the Week Ended June 8
Versartis (VSAR) stock rose 48.3% in the week of June 1–8. Versartis had consistent growth during the week, with 6.9% and 9.7% growth on June 4 and June 5, respectively. VSAR stock has risen ~50.9% over the last month. On June 4, Versartis entered into a merger agreement with Aravive Biologics.
- PR Newswire•17 days ago
Chief Executive Officer of Neurocrine Biosciences, Kevin Gorman, Ph.D., Named EY Entrepreneur Of The Year® 2018 San Diego
SAN DIEGO, June 8, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX), a San Diego based biotechnology company focused on neurological and endocrine related disorders, is proud to announce that Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences, received the Entrepreneur Of The Year® 2018 Award in the Life Sciences category in San Diego . The EY awards program recognizes entrepreneurs whose ingenuity, spirit of innovation and discipline have driven their companies' success, transformed their industries and made a positive impact on their communities.
Markit•17 days agoSee what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Simply Wall St.•23 days ago
What You Must Know About Neurocrine Biosciences Inc’s (NASDAQ:NBIX) Financial Strength
Mid-caps stocks, like Neurocrine Biosciences Inc (NASDAQ:NBIX) with a market capitalization of US$8.60B, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-capRead More...
- ACCESSWIRE•last month
Free Technical Insights on OPKO Health and Three Other Biotech Stocks
Stock Research Monitor: NBIX, NVAX, and ONTX LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want a free Stock Review on OPK sign up now at www.wallstequities.com/registration . On Monday, benchmark US ...
- GlobeNewswire•last month
Factors of Influence in 2018, Key Indicators and Opportunity within Fred's, Nexstar Broadcasting Group, CNO Financial Group, Neurocrine Biosciences, Kosmos Energy, and Loews — New Research Emphasizes Economic Growth
NEW YORK, May 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Fred's, ...
- PR Newswire•2 months ago
Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2018 Healthcare Conference
Live Audio Webcast Will be on May 15, 2018 SAN DIEGO , May 9, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Bank of America Merrill Lynch 2018 Healthcare Conference ...
- Motley Fool•2 months ago
3 Top Biotech Stocks to Buy in May
Looking for a few timely buys in the biotech space? Give these gems a closer look.
- PR Newswire•2 months ago
Neurocrine Biosciences Presents New Quality of Life Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia in Patients Treated with Antipsychotics
SAN DIEGO, May 8, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced new data from RE-KINECT, the largest real-world screening study to date of patients with clinician-confirmed possible tardive dyskinesia (TD), providing valuable insight into the impact of involuntary movements on the quality of life of patients taking antipsychotic medication. TD is a condition that is characterized by uncontrollable, abnormal and repetitive movements of the trunk, extremities and/or face, which may be disruptive and negatively impact patients.
- Zacks Small Cap Research•2 months ago
NBIX: Strong INGREZZA® Sales Continue in 1Q18; Expanding Sales Team for Future Growth
By David Bautz, PhD NASDAQ:NBIX INGREZZA® Launch Continues to go Well On April 30, 2018, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced financial results for the first quarter of 2018 and provided ...
- PR Newswire•2 months ago
Neurocrine Biosciences to Present New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2018 American Psychiatric Association Annual Meeting
SAN DIEGO, May 2, 2018 /PRNewswire/ -- Neurocrine Biosciences Inc. (NBIX) today announced that it will present new data from RE-KINECT, the largest real-world screening study to date of patients with clinician confirmed possible tardive dyskinesia (TD). This study is designed to better understand the potentially broad reaching impact of symptoms of possible TD on patients treated with antipsychotic medications.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of NBIX earnings conference call or presentation 30-Apr-18 9:00pm GMT
Q1 2018 Neurocrine Biosciences Inc Earnings Call
- Benzinga•2 months ago
Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on April 30) CareDx Inc (NASDAQ: CDNA ) Eleven Biotherapeutics Inc (NASDAQ: ...
- Associated Press•2 months ago
Neurocrine: 1Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 47 cents. The results missed Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research ...
- PR Newswire•2 months ago
Neurocrine Biosciences Reports First Quarter 2018 Financial Results
INGREZZA® (valbenazine) First Quarter Net Product Sales of $71.1 Million with Approximately 12,500 TRx Strong INGREZZA Demand Leads to Expansion of Sales Force Increased Investment in Tourette Syndrome ...
- ACCESSWIRE•2 months ago
Neurocrine Biosciences, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / April 30, 2018 / Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will be discussing their earnings results in their Q1 Earnings Call to be held on April 30, 2018 at 5:00 PM Eastern ...
- PR Newswire•2 months ago
AbbVie Presents New Investigational Data for Elagolix at the 2018 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting
- Seven presentations of elagolix data highlight AbbVie's research in endometriosis and uterine fibroids - Primary and secondary efficacy and safety data to be presented from two extension Phase 3 studies ...
Market Realist•2 months agoWhat Analysts Recommend for Neurocrine Biosciences in April 2018
In April 2018, the US FDA (Food and Drug Administration) notified Neurocrine Biosciences and AbbVie (ABBV) that it would require more time to review additional information associated with the liver function tests provided by AbbVie in addition to it its NDA (new drug application) for Elagolix. The US FDA granted the new PDUFA (Prescription Drug Fee User Act) action date in 3Q18.
Market Realist•2 months agoHow Neurocrine Biosciences Is Positioned ahead of 1Q18 Earnings
How Neurocrine Biosciences Is Positioned ahead of 1Q18 EarningsNeurocrine Biosciences revenue trends
- PR Newswire•2 months ago
Neurocrine Biosciences Presents New Data Analyses at AAN Annual Meeting Demonstrating INGREZZA® Improved Tardive Dyskinesia Symptoms Across Body Regions
Additional Long-Term Data Show INGREZZA Sustained Improvement of Tardive Dyskinesia Symptoms Through 48 Weeks of Treatment and was Well-Tolerated SAN DIEGO , April 25, 2018 /PRNewswire/ -- Neurocrine Biosciences, ...
- PR Newswire•2 months ago
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2018 Financial Results
Conference Call and Webcast Scheduled for Monday, April 30 SAN DIEGO , April 23, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report first quarter financial ...
- PR Newswire•2 months ago
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Neurocrine Biosciences, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK , April 19, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...
- PR Newswire•2 months ago
Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual Meeting
SAN DIEGO, April 18, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that new data for once-daily INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD), will be presented at the American Academy of Neurology (AAN) Annual Meeting in Los Angeles, Calif., April 21-27, 2018. Highlighted presentations include analysis of the short- and long-term effects of INGREZZA on TD symptoms by body region, long-term INGREZZA safety and efficacy data from the KINECT 4 Phase III open-label study and data from RE-KINECT, a real-world screening study of patients with possible TD. "The symptoms of tardive dyskinesia are heterogeneous, with each patient experiencing tardive dyskinesia somewhat differently.
Market Realist•2 months agoIngrezza: Boosting Neurocrine’s Top Line
Neurocrine Biosciences (NBIX) is a pharmaceutical company with a focus on neurological and endocrine-based diseases and disorders. Its leading product on the market is Ingrezza, a vesicular monoamine transporter 2 (or VMAT2) inhibitor used in the treatment of movement disorders. Ingrezza was approved by the FDA for the treatment of tardive dyskinesia (or TD) in April 2017.
